Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.